Profile data is unavailable for this security.
About the company
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
- Revenue in USD (TTM)0.00
- Net income in USD-40.68m
- Incorporated2009
- Employees25.00
- LocationPDS Biotechnology Corp303A College Road EastPRINCETON 08540United StatesUSA
- Fax+1 (908) 790-1212
- Websitehttps://www.pdsbiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annovis Bio Inc | 0.00 | -43.02m | 110.57m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 111.98m | 4.00 | -- | 5.14 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 114.09m | -- | 6.61 | 0.2309 | 59.00 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| INmune Bio Inc | 85.00k | -37.74m | 115.74m | 11.00 | -- | 2.77 | -- | 1,361.65 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Verastem Inc | 10.00m | -89.49m | 115.90m | 73.00 | -- | 4.11 | -- | 11.59 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 116.03m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 117.51m | 246.00 | -- | -- | -- | 0.3814 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 117.82m | 25.00 | -- | 3.81 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 119.13m | 93.00 | 8.25 | 1.26 | 6.60 | 211.60 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 119.15m | 31.00 | -- | 1.21 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 121.24m | 13.00 | -- | 9.73 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 123.29m | 65.00 | -- | 3.55 | -- | 5.74 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 124.75m | 31.00 | -- | 2.33 | -- | 187.60 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 124.97m | 140.00 | -- | 41.77 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Agenus Inc | 159.63m | -223.67m | 125.98m | 389.00 | -- | -- | -- | 0.7892 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 126.07m | 143.00 | -- | 0.5362 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Data as of Sep 20 2024. Currency figures normalised to PDS Biotechnology Corp's reporting currency: US Dollar USD
10.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.40m | 3.79% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 479.97k | 1.30% |
| Millennium Management LLCas of 30 Jun 2024 | 381.41k | 1.04% |
| Geode Capital Management LLCas of 30 Jun 2024 | 377.97k | 1.03% |
| Inspirion Wealth Advisors LLCas of 30 Jun 2024 | 359.89k | 0.98% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 317.46k | 0.86% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 240.12k | 0.65% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 135.46k | 0.37% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 130.53k | 0.36% |
| William Blair Investment Management LLCas of 30 Jun 2024 | 121.74k | 0.33% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
